» Articles » PMID: 36623713

Evaluation of Drug Carrier Hepatotoxicity Using Primary Cell Culture Models

Overview
Journal Nanomedicine
Publisher Elsevier
Date 2023 Jan 9
PMID 36623713
Authors
Affiliations
Soon will be listed here.
Abstract

This study aims to establish a primary rat hepatocyte culture model to evaluate dose-dependent hepatotoxic effects of drug carriers (lipopolymer nanoparticles; LPNs) temporal. Primary rat hepatocyte cell cultures were used to determine half-maximal Inhibition Concentrations (IC) of the drug-carrier library. Drug-carrier library, at concentrations <50 μg/mL, is benign to primary rat hepatocytes as determined using albumin and urea secretions. Albumin, as a hepatic biomarker, exhibited a more sensitive and faster outcome, compared to urea, for the determination of the IC value of LPNs. Temporal measurements of hepatic biomarkers including urea and albumin, and rigorous physicochemical (hydrodynamic diameter, surface charge, etc.) characterization, should be combined to evaluate the hepatotoxicity of drug carrier libraries in screens.

Citing Articles

SHINE: SERS-based Hepatotoxicity detection using Inference from Nanoscale Extracellular vesicle content.

Parlatan U, Boudreau L, Torun H, Fan L, Aygun U, Gokaltun A bioRxiv. 2025; .

PMID: 39974950 PMC: 11838255. DOI: 10.1101/2025.01.30.635446.


Development of Liver Cancer Organoids: Reproducing Tumor Microenvironment and Advancing Research for Liver Cancer Treatment.

Li K, Ren K, Du S, Gao X, Yu J Technol Cancer Res Treat. 2024; 23:15330338241285097.

PMID: 39363866 PMC: 11456184. DOI: 10.1177/15330338241285097.


Parallelized Droplet Vitrification Enables Single-Run Vitrification of the Whole Rat Liver Hepatocyte Yield.

Taggart M, Tchir A, Van Dieren L, Chen H, Hassan M, Taveras C bioRxiv. 2024; .

PMID: 39071342 PMC: 11275928. DOI: 10.1101/2024.07.14.603471.

References
1.
Tan X, Kim G, Lee D, Oh J, Kim M, Piao C . A curcumin-loaded polymeric micelle as a carrier of a microRNA-21 antisense-oligonucleotide for enhanced anti-tumor effects in a glioblastoma animal model. Biomater Sci. 2018; 6(2):407-417. DOI: 10.1039/c7bm01088e. View

2.
Amin M, Ali S, Ali M, Tariq I, Nasrullah U, Pinnapreddy S . Enhanced efficacy and drug delivery with lipid coated mesoporous silica nanoparticles in cancer therapy. Eur J Pharm Biopharm. 2021; 165:31-40. DOI: 10.1016/j.ejpb.2021.04.020. View

3.
Baeza A, Ruiz-Molina D, Vallet-Regi M . Recent advances in porous nanoparticles for drug delivery in antitumoral applications: inorganic nanoparticles and nanoscale metal-organic frameworks. Expert Opin Drug Deliv. 2016; 14(6):783-796. DOI: 10.1080/17425247.2016.1229298. View

4.
Yang F, Medik Y, Li L, Tian X, Fu D, Brouwer K . Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo. Small. 2020; 16(7):e1906360. PMC: 7873714. DOI: 10.1002/smll.201906360. View

5.
Ahmadian E, Babaei H, Nayebi A, Eftekhari A, Eghbal M . Mechanistic Approach for Toxic Effects of Bupropion in Primary Rat Hepatocytes. Drug Res (Stuttg). 2017; 67(4):217-222. DOI: 10.1055/s-0042-123034. View